PAASHEUVELWEG 25A, AMSTERDAM, P7
Announces Pricing of Upsized $225 Million Public Offering
Announces Preliminary Data on the First Cohort in the Phase I/IIa Clinical Trial of AMT-260 in Refractory Mesial Temporal Lobe Epilepsy
Announces Plan for BLA Submission for AMT-130 in Huntington’s Disease
Shareholders Approve Amendment to 2014 Share Incentive Plan
Announces Successful UK MHRA Pre-Submission Meeting for AMT-130 in Huntington’s Disease
Annual Report to Security Holders
Provides Regulatory Update on AMT-130 for Huntington’s Disease
Investor Presentation
Q1
FY 2025
Q3
Q2
FY 2024
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities to be Offered to Employees
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
Schedule 13G - Ownership Report
Amended Schedule 13G - Ownership Report